PMV Pharmaceuticals Business Summary

PMV Pharmaceuticals, Inc. (PMVP) is a clinical-stage precision oncology company that currently generates zero revenue, as its business model is entirely predicated on the research and development of small-molecule, tumor-agnostic therapies. The company operates through a single business segment focused on its proprietary discovery platform, which targets p53 mutations—the most common genetic alteration in human cancer. Its lead asset, rezatapopt (PC14586), is a first-in-class selective p53 reactivator currently in a pivotal Phase 2 trial (PYNNACLE) for solid tumors harboring the p53 Y220C mutation. PMV Pharmaceuticals competes primarily with other precision oncology and drug discovery firms such as Arcturus Therapeutics, Heron Therapeutics, and Frontier Medicines. Within this landscape, PMV occupies a specialized niche as a frontrunner in structurally correcting the p53 protein, aiming for a New Drug Application (NDA) submission in early 2027. The company was co-founded by Dr. Arnold Levine, a pioneer in the discovery of the p53 protein, and Dr. Thomas Shenk, a renowned virologist and professor at Princeton University. The leadership team is headed by President and CEO Dr. David H. Mack, a co-founder with extensive experience in biotechnology and genomic research. Key executives include Michael Carulli as Chief Financial Officer, Dr. Deepika Jalota as Chief Development Officer, and Robert Ticktin as Chief Operating Officer and General Counsel. The board is chaired by Dr. Richard Heyman, a notable biotech entrepreneur with a track record of high-value exits including RayzeBio and Aragon Pharmaceuticals. PMV is backed by prominent institutional investors such as OrbiMed, RA Capital Management, and Viking Global Investors, maintaining a cash runway that extends into 2027 to support its registrational clinical milestones.